Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis

Tina Rike Herold,1 Veronika Jakl,3 Anno Graser,4 Kirsten Eibl-Lindner1,21Department of Ophthalmology, 2Department of Ophthalmology, Campus Innenstadt, 3Department of Neurology, 4Department of Clinical Radiology, Campus Grosshadern, University of Munich, Ludwig-Maximilians University, Munich, Germany...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Herold TR, Jakl V, Graser A, Eibl-Lindner K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/bcaa3461541c4252bb46b7feb1a3b513
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bcaa3461541c4252bb46b7feb1a3b513
record_format	dspace
spelling	oai:doaj.org-article:bcaa3461541c4252bb46b7feb1a3b5132021-12-02T11:40:47ZHemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis1177-54671177-5483https://doaj.org/article/bcaa3461541c4252bb46b7feb1a3b5132012-07-01T00:00:00Zhttp://www.dovepress.com/hemianopia-and-visual-loss-due-to-progressive-multifocal-leukoencephal-a10431https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Tina Rike Herold,1 Veronika Jakl,3 Anno Graser,4 Kirsten Eibl-Lindner1,21Department of Ophthalmology, 2Department of Ophthalmology, Campus Innenstadt, 3Department of Neurology, 4Department of Clinical Radiology, Campus Grosshadern, University of Munich, Ludwig-Maximilians University, Munich, GermanyAbstract: This case describes typical ophthalmic findings as a key feature for diagnosis of progressive multifocal leukoencephalopathy (PML) and its possible differential diagnosis. A 58-year-old female patient with relapsing-remitting multiple sclerosis on immunotherapy with natalizumab developed visual disturbance, reading problems, and visual field defects due to PML. PML is a reactivation of latent infection with the John Cunningham virus, which is a type of polyomavirus acquired in childhood or adolescence and is quite common in the general population. PML so far has been mostly associated with other immunodeficiency disorders, such as acquired immunodeficiency syndrome, but is also gaining importance in association with the increasing use and duration of treatment with natalizumab in patients suffering from multiple sclerosis. Natalizumab is a highly specific &alpha;4-integrin antagonist approved for treatment of patients with active relapsing-remitting multiple sclerosis.Keywords: progressive multifocal leukoencephalopathy, natalizumab, multiple sclerosis, hemianopiaHerold TRJakl VGraser AEibl-Lindner KDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1131-1133 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Herold TR Jakl V Graser A Eibl-Lindner K Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
description	Tina Rike Herold,1 Veronika Jakl,3 Anno Graser,4 Kirsten Eibl-Lindner1,21Department of Ophthalmology, 2Department of Ophthalmology, Campus Innenstadt, 3Department of Neurology, 4Department of Clinical Radiology, Campus Grosshadern, University of Munich, Ludwig-Maximilians University, Munich, GermanyAbstract: This case describes typical ophthalmic findings as a key feature for diagnosis of progressive multifocal leukoencephalopathy (PML) and its possible differential diagnosis. A 58-year-old female patient with relapsing-remitting multiple sclerosis on immunotherapy with natalizumab developed visual disturbance, reading problems, and visual field defects due to PML. PML is a reactivation of latent infection with the John Cunningham virus, which is a type of polyomavirus acquired in childhood or adolescence and is quite common in the general population. PML so far has been mostly associated with other immunodeficiency disorders, such as acquired immunodeficiency syndrome, but is also gaining importance in association with the increasing use and duration of treatment with natalizumab in patients suffering from multiple sclerosis. Natalizumab is a highly specific &alpha;4-integrin antagonist approved for treatment of patients with active relapsing-remitting multiple sclerosis.Keywords: progressive multifocal leukoencephalopathy, natalizumab, multiple sclerosis, hemianopia
format	article
author	Herold TR Jakl V Graser A Eibl-Lindner K
author_facet	Herold TR Jakl V Graser A Eibl-Lindner K
author_sort	Herold TR
title	Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
title_short	Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
title_full	Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
title_fullStr	Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
title_full_unstemmed	Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
title_sort	hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/bcaa3461541c4252bb46b7feb1a3b513
work_keys_str_mv	AT heroldtr hemianopiaandvisuallossduetoprogressivemultifocalleukoencephalopathyinnatalizumabtreatedmultiplesclerosis AT jaklv hemianopiaandvisuallossduetoprogressivemultifocalleukoencephalopathyinnatalizumabtreatedmultiplesclerosis AT grasera hemianopiaandvisuallossduetoprogressivemultifocalleukoencephalopathyinnatalizumabtreatedmultiplesclerosis AT eibllindnerk hemianopiaandvisuallossduetoprogressivemultifocalleukoencephalopathyinnatalizumabtreatedmultiplesclerosis
_version_	1718395542512336896

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis

Ejemplares similares